Abstract: Provided is a fusion protein of insulin and an immunoglobulin Fc region. Specifically, the present invention relates to an insulin fusion protein having a prolonged in vivo half-life and stability, a preparation that contains the fusion protein, a preparation method therefor and an application thereof.

Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.

Abstract: Provided are a blood coagulation factor IX fusion protein with a prolonged circulation half-life, a conjugate thereof, a pharmaceutical composition containing same and the use of same in treating hemorrhagic diseases (such as hemophilia B).

Abstract: Provided by the present invention are a novel GLP-1 fusion protein and a conjugate thereof, a pharmaceutical composition containing same, and a use thereof in reducing blood sugar or body weight, especially for treating diabetes, in particular type II diabetes.

Abstract: Disclosed are a coagulation factor VIII fusion protein which is conjugated with polyalkylene glycol and which has an extended cyclic half-life, a preparation method therefor and a use thereof, wherein the active moiety of the coagulation factor VIII is directly linked or indirectly linked by a peptide linker to a fusion partner, and the fusion protein is further conjugated to a polyalkylene glycol. The half-life is significantly increased compared to an FVIII fusion protein modified without polyalkylene glycol.

Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.